Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN) have been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $8.75.

A number of equities analysts recently weighed in on AGEN shares. StockNews.com upgraded shares of Agenus from a “sell” rating to a “hold” rating in a research report on Friday, March 21st. HC Wainwright reissued a “neutral” rating on shares of Agenus in a report on Tuesday, March 18th. Finally, Robert W. Baird cut their price objective on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a research report on Wednesday, March 12th.

Agenus Stock Up 1.8 %

NASDAQ AGEN opened at $1.67 on Wednesday. Agenus has a twelve month low of $1.55 and a twelve month high of $19.69. The business has a 50-day moving average price of $2.95 and a 200-day moving average price of $3.61. The firm has a market cap of $42.27 million, a price-to-earnings ratio of -0.15 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The business had revenue of $26.84 million during the quarter, compared to analysts’ expectations of $30.09 million. Research analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Agenus

Several institutional investors have recently bought and sold shares of AGEN. Corton Capital Inc. bought a new stake in shares of Agenus in the 4th quarter worth about $36,000. Virtu Financial LLC purchased a new position in Agenus in the fourth quarter worth about $51,000. Apollon Wealth Management LLC bought a new stake in Agenus during the fourth quarter worth approximately $55,000. EP Wealth Advisors LLC purchased a new stake in Agenus during the third quarter valued at approximately $55,000. Finally, Bank of Montreal Can bought a new stake in shares of Agenus in the 4th quarter valued at approximately $69,000. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.